Literature DB >> 23482913

Fetal and neonatal alloimmune thrombocytopenia.

Simona Constantinescu1, Vlad Zamfirescu, Prof Radu Vladareanu.   

Abstract

UNLABELLED: Fetal and neonatal alloimmune thrombocytopenia (FNAIT) is the commonest cause of severe neonatal thrombocytopenia. FNAIT is usually suspected in neonates with bleeding or severe, unexplained, and/or isolated postnatal thrombocytopenia. Affected fetuses should be managed in referral centers with experience in the ante-natal management of FNAIT. Close collaboration is required between specialists in fetal medicine, obstetrics, hematology/transfusion medicine, and pediatrics. The mother and her partner should be provided with detailed information about FNAIT and its potential clinical consequences, and the benefits and risks of different approaches to ante-natal management. There has been huge progress in the ante-natal management of FNAIT over the last 20 years. However, the ideal effective treatment without significant side effects to the mother or fetus has yet to be determined. KEY ISSUES: Fetal and neonatal alloimmune thrombocytopenia is a condition that is underdiagnosed.Immunization seldom occurs in the first pregnancy.Immunization takes place in association with delivery in most cases.Anti-HPA-1a level is a predictor for the severity of thrombocytopenia.

Entities:  

Keywords:  fetus; human platelet antigen; intracranial haemorrage; thrombocytopenia; transfusion

Year:  2012        PMID: 23482913      PMCID: PMC3593293     

Source DB:  PubMed          Journal:  Maedica (Buchar)        ISSN: 1841-9038


  15 in total

1.  Provision of platelet support for fetuses and neonates affected by severe fetomaternal alloimmune thrombocytopenia.

Authors:  E Ranasinghe; J D Walton; C M Hurd; L Saul; G Smith; K Campbell; W H Ouwehand
Journal:  Br J Haematol       Date:  2001-04       Impact factor: 6.998

2.  Guidelines for the use of platelet transfusions.

Authors: 
Journal:  Br J Haematol       Date:  2003-07       Impact factor: 6.998

Review 3.  Fetal alloimmune thrombocytopenia: consensus and controversy.

Authors:  J B Bussel; D W Skupski; J G MacFarland
Journal:  J Matern Fetal Med       Date:  1996 Sep-Oct

4.  Fetal alloimmune thrombocytopenia.

Authors:  J B Bussel; M R Zabusky; R L Berkowitz; J G McFarland
Journal:  N Engl J Med       Date:  1997-07-03       Impact factor: 91.245

Review 5.  Management of alloimmune neonatal and antenatal thrombocytopenia.

Authors:  M F Reznikoff-Etievant
Journal:  Vox Sang       Date:  1988       Impact factor: 2.144

6.  Prenatal intracranial hemorrhage and neurologic complications in alloimmune thrombocytopenia.

Authors:  U Sharif; K Kuban
Journal:  J Child Neurol       Date:  2001-11       Impact factor: 1.987

Review 7.  Feto-maternal alloimmune thrombocytopenia: a literature review and statistical analysis.

Authors:  J A Spencer; R F Burrows
Journal:  Aust N Z J Obstet Gynaecol       Date:  2001-02       Impact factor: 2.100

8.  Antenatal management of severe feto-maternal alloimmune thrombocytopenia: HLA incompatibility may affect responses to fetal platelet transfusions.

Authors:  M F Murphy; P Metcalfe; A H Waters; J Ord; H Hambley; K Nicolaides
Journal:  Blood       Date:  1993-04-15       Impact factor: 22.113

9.  A prospective study of maternal anti-HPA 1a antibody level as a potential predictor of alloimmune thrombocytopenia in the newborn.

Authors:  Mette Kjaer Killie; Anne Husebekk; Jens Kjeldsen-Kragh; Bjørn Skogen
Journal:  Haematologica       Date:  2008-04-28       Impact factor: 9.941

10.  T-cell responses associated with neonatal alloimmune thrombocytopenia: isolation of HPA-1a-specific, HLA-DRB3*0101-restricted CD4+ T cells.

Authors:  Maria Therese Ahlen; Anne Husebekk; Mette Kjaer Killie; Bjørn Skogen; Tor B Stuge
Journal:  Blood       Date:  2009-01-09       Impact factor: 22.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.